This final episode in KDIGO’s four-part IgAN series focuses on the challenges and opportunities of implementing the updated KDIGO IgAN Guideline in clinical practice. The conversation examines a shifting treatment paradigm that emphasizes earlier intervention and simultaneous, multi-targeted therapy, while addressing persistent barriers to guideline adoption, including gaps in disease awareness, diagnostic precision, and risk stratification. Drawing on insights from recent clinical trials, the discussion also explores how emerging evidence is shaping therapeutic decision-making, highlights priority areas for future IgAN research, and considers what continued innovation may mean for improving long-term patient outcomes.The episode is hosted by Dana Rizk, MD (University of Alabama at Birmingham, United States), and features Suneel Udani, MD (United States). Previous episodes in the series feature KDIGO IgAN Guideline Co-Chair Brad Rovin, MD (The Ohio State University College of Medicine, United States), Shikha Wadwani, MD (Cedars Sinai, United States), and Gaia Coppock, MD (United States).This podcast series was supported by Travere.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related